Pharnext 
Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of 
PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A') 
31-March-2021 / 08:30 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of 
PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A') 
 
 
PARIS, France, March 31, 2021, 8:30 a.m. CET - Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced 
late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations 
based on big genomics data and artificial intelligence using its PLEOTHERAPY(TM) platform, today announces that the 
first subject has been enrolled in its pivotal Phase III clinical study ('PREMIER trial') of PXT3003 in the U.S. at the 
Austin Neuromuscular Center (Texas). PXT3003 is the Company's lead program to treat Charcot-Marie-Tooth disease type 1A 
('CMT1A'), an indication with currently no existing approved therapies. The trial will enroll approximately 350 
subjects with mild-to-moderate CMT1A in 50 centers in the U.S., Canada, Europe, and Israel. 
 
The PREMIER trial is a randomized, double-blind, two-arm placebo-controlled, pivotal Phase III study, evaluating the 
efficacy and safety of PXT3003 versus placebo in CMT1A patients, over a 15-month period. The dose of PXT3003 tested in 
the PREMIER trial corresponds to the high dose tested in the prior Phase III trial ('PLEO-CMT'). As agreed with 
regulatory agencies, the primary efficacy endpoint will be the Overall Neuropathy Limitations Scale ('ONLS') which 
measures functional motor disability. The secondary endpoints include the following outcome measures: 1) 10-Meter Walk 
Test ('10mWT'), 2) Quantified Muscular Testing (bilateral foot dorsiflexion dynamometry), 3) Patient Global Impression 
of Severity ('PGI-S'), 4) Patient Global Impression of Change ('PGI-C'), 5) Charcot-Marie-Tooth Neuropathy Score, 
version 2 ('CMTNS-v2'), and 6) Quantified Muscular Testing (hand grip). Safety and tolerability will be monitored 
throughout the study. Further information on the PREMIER trial, including potential timelines, can be found on the 
ClinicalTrials.gov website (study identification number: NCT04762758) here. 
 
Adrian Hepner, MD, PhD, Chief Medical Officer of Pharnext, said: "PXT3003 has already shown an encouraging response in 
our prior Phase II and Phase III ('PLEO-CMT') trials using the ONLS, and we place high hope that the efficacy and 
safety of PXT3003 will be further demonstrated in our PREMIER trial. CMT1A is a severe, debilitating, chronic inherited 
neuropathy representing a serious unmet medical need and the initiation of the PREMIER trial shows we are now on a 
clear path forward for PXT3003 as we seek to help patients with CMT1A." 
 
Mario Saporta, MD, PhD, Associate Professor of Neurology and Human Genetics and Director of CMT Center of Excellence at 
Miller School of Medicine at the University of Miami and lead investigator of the PREMIER trial in North America, said: 
'The PREMIER trial is an important milestone for those suffering from this debilitating disease and it is encouraging 
to see the first patient being dosed at a U.S. center." 
 
Shahram Attarian, MD, PhD, Head of the Neuromuscular Diseases and ALS department at the University Hospital La Timone 
in Marseille (France), Coordinator of the FILNEMUS Rare Diseases Network and Neuromuscular Diseases Reference Centers 
in France, and Lead Investigator of the PREMIER trial in Europe, said: "This is an essential step forward for PXT3003 
and developing an accessible potential treatment for patients suffering from CMT1A. I look forward to seeing the 
patients being dosed in the PREMIER trial across European centers over the coming weeks." 
 
If primary endpoints are met in the PREMIER trial and a pre-clinical combination factorial study in a well-established 
and validated CMT1A animal model, the results of both studies will form the efficacy and safety basis for the New Drug 
Application ('NDA') submission to the FDA and the Marketing Authorization submission to the EMA for PXT3003. 
 
Based on timing considerations due to the FDA's feedback on our Special Protocol Assessment ('SPA') coinciding with the 
start of the PREMIER Trial, Pharnext has decided not to further pursue the SPA process that was initiated in Q3 2020. 
While the FDA has provided positive and constructive feedback and has stated that the overall design of the PREMIER 
trial may be appropriate for a SPA designation, a full agreement was not reached on the management of data at sites 
that may be affected by the COVID-19 pandemic, as detailed in the statistical analysis plan. Given the FDA's alignment 
on all the major elements of the PREMIER study design and consequently the absence of impact on the operational 
implementation of the trial, the Company has chosen to start the PREMIER trial without further delay and will continue 
to monitor and comply with the FDA guidance on clinical trials conducted during the COVID-19 pandemic. 
 
 
About Charcot-Marie-Tooth Disease Type 1A ('CMT1A') 
Charcot-Marie-Tooth ('CMT') disease encompasses a heterogeneous group of inherited, severe, debilitating, progressive 
and chronic peripheral neuropathies. CMT1A, the most common type of CMT, is an orphan disease with a prevalence of 1/ 
5000 people affecting about 150,000 people in Europe and the U.S. and about 1,500,000 people worldwide. The genetic 
mutation responsible for CMT1A is a duplication of the PMP22 gene coding for a peripheral myelin protein. The 
duplication of this gene results in overexpression of the PMP22 protein and failure of Schwann cells to produce normal 
myelin (neuronal sheath). The lack of a normal myelin structure and function leads to abnormal peripheral nerve 
conduction and axonal loss. As a result of peripheral nerve degradation, patients suffer from progressive muscle 
atrophy in both the legs and arms causing problems with walking, running and balance as well as abnormal hand 
functioning. They might also suffer from mild to moderate sensory disorders. First symptoms usually appear during 
adolescence and will progressively evolve throughout life. Patients with the most severe form of CMT1A end up in 
wheelchairs, representing at least 5% of cases. To date, no curative or symptomatic medications have been approved and 
treatment consists of supportive care such as orthotics, leg braces, physical and occupational therapy or surgery. More 
information can be found at https://pharnext.com/en/disease/charcot-marie-tooth. 
 
 
About PXT3003 
PXT3003 is a novel fixed-dose synergistic combination of baclofen, naltrexone and sorbitol formulated as an oral 
solution given twice a day. The three individual components of PXT3003 were selected to downregulate the overexpression 
of PMP22 protein, leading to improvement of neuronal signaling in dysfunctional peripheral nerves that are an essential 
part of the pathophysiology of this disease. PXT3003 could also have a positive effect on other cellular types of the 
motor unit such as the axon (direct protection), neuromuscular junctions or muscle cells. PXT3003 has shown promising 
and consistent results across preclinical and clinical studies in Phase II and Phase III (PLEO-CMT). More information 
can be found at https://pharnext.com/en/pipeline/pxt3003. 
 
 
About Pharnext 
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common 
neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead 
products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for 
the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United 
States. PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through 
partnerships. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial 
intelligence: PLEOTHERAPY(TM). Pharnext identifies and develops synergic combinations of drugs called PLEODRUG(TM). 
More information can be found at www.pharnext.com. 
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). 
 
 
Disclaimer 
This press release contains certain forward-looking statements concerning Pharnext and its business, including in 
respect of timing of and prospects for clinical trials and regulatory submissions of the Company's product candidates 
as well as a potential financing transaction, the use of proceeds therefrom and cash runway. Such forward-looking 
statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that 
the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous 
risks including the risks set forth in Pharnext's URD approved by the AMF on November 9, 2020 under number N° R. 20-029 
as well as in its annual periodic management reports and press releases (copies of which are available on 
www.pharnext.com) and to the development of economic conditions, financial markets and the markets in which Pharnext 
operates. The forward-looking statements contained in this press release are also subject to risks not yet known to 
Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause 
actual results, financial conditions, performance or achievements of Pharnext to be materially different from such 
forward-looking statements. Pharnext disclaims any intention or obligation to publicly update or revise any

(MORE TO FOLLOW) Dow Jones Newswires

March 31, 2021 02:32 ET (06:32 GMT)